All News
Eric Dein ericdeinmd ( View Tweet)
TheDaoIndex KDAO2011 ( View Tweet)
Anti-Drug Antibodies and Biologic Drug Responses
A prospective cohort study suggests the presence of antidrug antibodies may be associated with bDMARDs nonresponse in rheumatoid arthritis (RA). Should we be monitoring ADAbs (especially in nonresponders)?
Read Article
Prevalence of Cardiovascular Disease in Rheumatoid Arthritis
A prospective study of the BioSTAR registry estimates the prevalence of cardiovascular disease in rheumatoid arthritis (RA) to be 4.6%.
Read Article
Best Treatments for COVID-Related MIS-C
The RECOVERY trial focused on pediatric MIS-C patients treated with immunomodulators and anti-cytokine therapy demonstrated the benefits of first-line therapy with intravenous methylprednisolone or second-line tocilizumab in children refractory to initial treatment.
Read Article
ACR Applauds Prior Authorization Rule
The American College of Rheumatology (ACR), on behalf of over 9,100 rheumatologists and rheumatology professional team members, applauds the Centers for Medicare and Medicaid Services (CMS) for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Adva
Read Article
Methotrexate Nodulosis (1.19.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. How good (or not) are rheumatologists and what to do about MTX nodulosis?
Read Article
Links:
Rituximab Efficacy in MAINRITSAN Long-Term Studies
The original randomized controlled, prospective MAINRITSAN study of 115 patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis [AAV]) demonstrated superiority of rituximab (RTX) over azathioprine (AZA) for maintenance of remission at 22 months in ANCA-associated vasculitis patients after CYC remission induction.
Read Article
Links:
CMS Final Rule on Prior Authorization Reforms
Prior authorizations and paperwork are killing medical providers; the good news is that a new CMS rule may lessen the burden.
The Centers for Medicare & Medicaid Services (CMS) has announced that they have finalized the CMS Interoperability and Prior Authorization Final Rule, designed to improve prior authorization processes and reduce burden on patients, providers, and payers, with a resultant $15 billion of estimated savings over ten years.